Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025
Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...
Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...
Researchers find a hint at how to delay Alzheimer’s symptoms. Now they have to prove it
The new findings center on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight ...
HC Wainwright Reiterates “Buy” Rating for Immunovant (NASDAQ:IMVT)
Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in ...
Research Analysts Issue Forecasts for RNAC FY2025 Earnings
Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Cartesian Therapeutics in a report released on Monday, March 17th. Cantor Fitzgerald analyst K. Kluska forecasts that the company ...